CA
NZ
UK
AU
IND
US
…
Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine; and development agreement with the University of Pennsylvania School of Veterinary Medicine for the development of a metformin-based ophthalmic formulation. Curative Biotechnology, Inc. was founded in 1995 and is headquartered in Palm Beach Gardens, Florida.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Curative Biotechnology Inc is a small-cap biotechnology company listed on NYSE American; public filings offer limited detail on its pipeline and commercial operations. Long-term growth may hinge on clinical or regulatory progress, strategic partnerships and successful capital raises, which could support program advancement and attract investors seeking early-stage biotech upside.
Key risks include limited disclosure, apparent early-stage status with no established revenues, execution and financing uncertainty, and sensitivity to regulatory outcomes.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -2.26M | -3.56M | -3.96M | -5.60M | -5.34M |
| Net income | -2.26M | -3.56M | -3.96M | -5.60M | -5.34M |
| Selling general administrative | - | 2.25M | 1.56M | 1.95M | 4.21M |
| Gross profit | -0.09M | -0.09M | -0.10M | 0.00M | 0.00M |
| Reconciled depreciation | - | - | - | 0.01M | 0.01M |
| Ebit | -1.50M | -2.44M | -2.60M | -4.43M | -5.00M |
| Ebitda | -1.41M | -2.35M | -2.50M | -4.42M | -4.99M |
| Depreciation and amortization | 0.09M | 0.09M | 0.10M | 0.01M | 0.01M |
| Operating income | -1.50M | -2.44M | -1.93M | -4.44M | -5.01M |
| Other operating expenses | 1.50M | 2.44M | 1.93M | 4.44M | 5.00M |
| Interest expense | 1.00M | 1.12M | 1.36M | 1.17M | 0.18M |
| Net interest income | - | - | - | -1.17M | -0.18M |
| Income tax expense | - | - | -0.00M | 1.18M | 0.18M |
| Total revenue | - | - | - | 0.00M | 0.00M |
| Total operating expenses | 1.41M | 2.35M | 1.83M | 4.44M | 5.00M |
| Cost of revenue | 0.09M | 0.09M | 0.10M | 0.00M | 0.00M |
| Total other income expense net | -0.76M | -1.12M | -2.02M | 0.00M | -0.17M |
| Net income from continuing ops | - | - | - | -5.60M | -5.34M |
| Net income applicable to common shares | - | - | - | - | -18.82M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 2.11M | 2.16M | 2.60M | 2.09M | 2.41M |
| Intangible assets | 1.31M | 1.35M | 1.42M | - | - |
| Other current assets | 0.06M | 0.19M | 0.43M | - | - |
| Total liab | 8.20M | 7.08M | 5.75M | 22.62M | 18.77M |
| Total stockholder equity | -6.09M | -4.91M | -3.14M | -20.53M | -16.36M |
| Deferred long term liab | - | - | - | - | 0.09M |
| Other current liab | 6.84M | 1.58M | 0.00M | 3.42M | 0.73M |
| Common stock | 0.00M | 0.09M | 0.09M | 0.06M | 0.00M |
| Capital stock | - | - | - | 0.06M | 0.00M |
| Retained earnings | -44.77M | -41.89M | -38.23M | -32.61M | -26.92M |
| Other assets | - | 0.00M | - | - | 0.09M |
| Cash | 0.05M | 0.02M | 0.06M | 0.06M | 0.67M |
| Total current liabilities | 8.20M | 7.08M | 5.75M | 4.49M | 0.73M |
| Current deferred revenue | - | - | -3.49M | - | - |
| Net debt | 1.31M | 1.35M | 2.20M | 1.01M | -0.67M |
| Short term debt | 1.36M | 1.37M | 2.26M | 1.07M | - |
| Short long term debt | - | - | - | 1.07M | - |
| Short long term debt total | 1.36M | 1.37M | 2.26M | 1.07M | - |
| Other stockholder equity | 38.68M | 36.88M | 34.99M | 12.02M | 10.56M |
| Property plant equipment | - | - | - | - | 0.01M |
| Total current assets | 0.11M | 0.21M | 0.60M | 0.07M | 0.75M |
| Net tangible assets | - | - | - | - | -17.92M |
| Net receivables | - | - | 0.12M | - | 0.03M |
| Inventory | - | - | -0.12M | - | - |
| Accounts payable | - | 4.13M | 3.49M | - | 0.73M |
| Accumulated other comprehensive income | - | - | 0.00M | - | - |
| Non currrent assets other | 0.69M | 0.60M | 0.57M | 0.39M | 0.09M |
| Non current assets total | 2.00M | 1.95M | 2.00M | 2.02M | 1.66M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | - | - | -0.08M | -0.02M |
| Change to liabilities | - | - | - | - | 0.59M |
| Total cashflows from investing activities | - | - | -0.01M | - | -0.02M |
| Net borrowings | - | - | - | - | 0.13M |
| Total cash from financing activities | 0.89M | 0.99M | 0.50M | 1.00M | 2.14M |
| Change to operating activities | - | - | - | - | -0.04M |
| Net income | -2.26M | -3.56M | -3.96M | -5.60M | -5.34M |
| Change in cash | 0.03M | -0.04M | -0.00M | -0.61M | 0.51M |
| Begin period cash flow | 0.02M | 0.06M | 0.06M | 0.67M | 0.16M |
| End period cash flow | 0.05M | 0.02M | 0.06M | 0.06M | 0.67M |
| Total cash from operating activities | -0.87M | -1.02M | -0.49M | -1.54M | -1.60M |
| Issuance of capital stock | - | - | - | 0.12M | 1.57M |
| Depreciation | 0.09M | 0.09M | 0.09M | 0.01M | 0.01M |
| Other cashflows from investing activities | - | - | -0.01M | - | - |
| Other cashflows from financing activities | 0.26M | 0.09M | -0.08M | 1.09M | 0.61M |
| Change to netincome | - | - | - | - | 3.18M |
| Capital expenditures | 0.00M | 0.00M | 0.01M | 0.08M | 0.02M |
| Change in working capital | 0.51M | 0.83M | -0.05M | 2.74M | 0.55M |
| Stock based compensation | - | - | 0.23M | 0.28M | 2.89M |
| Other non cash items | 0.79M | 1.62M | 3.20M | 1.04M | 0.29M |
| Free cash flow | -0.87M | -1.02M | -0.50M | -1.61M | -1.63M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| CUBT Curative Biotechnology Inc |
-0.18 21.63% |
0.65 | - | - | 158.53 | - | -3.88 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine; and development agreement with the University of Pennsylvania School of Veterinary Medicine for the development of a metformin-based ophthalmic formulation. Curative Biotechnology, Inc. was founded in 1995 and is headquartered in Palm Beach Gardens, Florida.
3801 PGA Blvd, Palm Beach Gardens, FL, United States, 33410
561 907 8990
| Name | Title | Year Born |
|---|---|---|
| Mr. Paul M. Michaels | Pres & Exec. Chairman | 1966 |
| Mr. I. Richard Garr Esq., J.D. | CEO, CFO, Principal Accounting Officer & Gen. Counsel | 1953 |
| Dr. Barry A. Ginsberg B.A., B.S. | Chief Strategy Officer, Vice Chairman and Member of Scientific & Clinical Advisory Board | 1957 |
| Mr. Pam Bisikirski | VP of Communications | NA |
| Dr. Ronald Bordens Ph.D. | Exec. VP of Process Product Drug Devel. and Member of Scientific & Clinical Advisory Board | NA |
| Mr. Paul M. Michaels | President & Executive Chairman | 1966 |
| Mr. I. Richard Garr Esq., J.D. | CEO, CFO, Principal Accounting Officer & General Counsel | 1953 |
| Ms. Pam Bisikirski | Vice President of Communications | NA |
| Dr. Ronald Bordens Ph.D. | Executive VP of Process Product Drug Development and Member of Scientific & Clinical Advisory Board | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...